Insmed (NASDAQ: INSM) reported Q3 EPS of ($1.75), $0.41 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $142 million versus the consensus estimate of $114.87 million.

GUIDANCE:

Insmed sees FY2025 revenue of $420-430 million, versus the consensus of $471.3 million.

For earnings history and earnings-related data on Insmed (INSM) click here.